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Abstract K201 has previously been shown to reduce
diastolic contractions in vivo during b-adrenergic stimu-
lation and elevated extracellular calcium concentration
([Ca
2?]o). The present study characterised the effect of
K201 on electrically stimulated and spontaneous diastolic
sarcoplasmic reticulum (SR)-mediated Ca
2? release and
contractile events in isolated rat cardiomyocytes during
b-adrenergic stimulation and elevated [Ca
2?]o. Parallel
experiments using confocal microscopy examined sponta-
neous diastolic Ca
2? release events at an enhanced spa-
tiotemporal resolution. 1.0 lmol/L K201 in the presence of
150 nmol/L isoproterenol (ISO) and 4.75 mmol/L [Ca
2?]o
signiﬁcantly decreased the amplitude of diastolic
contractions to *16% of control levels. The stimulated
free Ca
2? transient amplitude was signiﬁcantly reduced,
but stimulated cell shortening was not signiﬁcantly altered.
When intracellular buffering was taken into account, K201
led to an increase in action potential-induced SR Ca
2?
release. Myoﬁlament sensitivity to Ca
2? was not changed
by K201. Confocal microscopy revealed diastolic events
composed of multiple Ca
2? waves (2–3) originating at
various points along the cardiomyocyte length during each
diastolic period. 1.0 lmol/L K201 signiﬁcantly reduced the
(a) frequency of diastolic events and (b) initiation points/
diastolic interval in the remaining diastolic events to 61%
and 71% of control levels respectively. 1.0 lmol/L K201
can reduce the probability of spontaneous diastolic Ca
2?
release and their associated contractions which may limit
the propensity for the contractile dysfunction observed
in vivo.
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Abbreviations
[Ca
2?]i Intracellular calcium concentration
[Ca
2?]o Extracellular calcium concentration
DAD Delayed after depolarisations
DD Diastolic dysfunction
F/F0 Quiescent ﬂuorescence
ICa L-type Ca
2? current
KH Krebs–Henseleit solution
NCX Sodium–calcium exchanger
NE Nor-epinephrine
RCL Resting cell length
RyR2 Ryanodine receptor
SERCA Sarcoplasmic/endoplasmic Ca
2? ATPase pump
SR Sarcoplasmic reticulum
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Sarcoplasmic reticulum (SR)-mediated Ca
2? handling
(which includes Ca
2? uptake via the sarcoplasmic/endo-
plasmic Ca
2? ATPase pump, SERCA, and Ca
2? release via
the ryanodine receptor, RyR2) is altered in almost all
models of heart failure and may lead to abnormal myo-
cardial relaxation and ﬁlling during diastole [5, 6, 15, 22].
While many studies have correlated the consequences of
altered SERCA-mediated Ca
2? uptake and diastolic dys-
function (DD) [1, 20], few have investigated the conse-
quences of abnormal diastolic SR Ca
2? release on whole
heart contractile function. To address this issue, a recent
study by the authors demonstrated that while in vivo
administration of a b-adrenergic agonist or an elevated
extracellular calcium concentration ([Ca
2?]o) separately
did not produce any signiﬁcant alteration of diastolic
function in rat hearts, co-administration of a b-adrenergic
agonist and an elevated [Ca
2?]o led to an acute onset of DD
[13]. A b-adrenergic agonist was used in this in vivo model
to stimulate a PKA-mediated increase in SR Ca
2? load.
When combined with an elevated [Ca
2?]o, DD manifest as
diastolic contractions, a raised end-diastolic pressure
(EDP) but no alteration of ejection fraction [13].
K201 (JTV-519), a 1,4 benzothiazepine derivative
structurally distinct from diltiazem, was originally dis-
covered when screening compounds to prevent sudden
cardiac cell death in a rat Langendorff model of myoﬁbr-
illar over-contraction [12]. The drug has been suggested to
improve contractile function in heart failure via a sole
inhibitory effect on diastolic RyR2-mediated SR Ca
2?
release [27, 29]. However, it is clear from the literature that
K201 exhibits effects on additional cellular targets in a
species-speciﬁc manner [3]. In guinea pig cardiomyocytes,
K201 inhibits sodium (INa)[ 16] and potassium currents
(IK1, IKr)[ 16, 17] and prolongs action potential duration
[17], yet the effect on these targets has not been determined
in alternative species. Investigations of the effect on L-type
calcium current (ICa) have yielded contrasting results with
inhibition in the rat and guinea pig [11, 14], whilst no effect
in the rabbit [18]. Inhibition of SERCA activity by K201 in
rabbit cardiomyocytes has been demonstrated previously,
but the effect in rat is unknown [18]. In the above rat model
of DD, K201 limits diastolic contractures and reduces EDP
[14] in vivo; however, the cellular mechanisms underlying
these phenomena are unknown. It is possible that the
observed beneﬁt of K201 in vivo could originate from the
drugs ability to (a) inhibit abnormal diastolic Ca
2? release
events leading to improved contractile performance or
(b) alteration of myoﬁlament Ca
2? sensitivity. To test these
hypotheses and given K201’s species speciﬁcity, this
study was designed to characterise the effect of K201 on:
(a) the stimulated Ca
2? transient and cell shortening,
(b) spontaneous Ca
2? release and the corresponding
spontaneous contractile event, (c) myoﬁlament sensitivity
to Ca
2? and (d) SR function, in isolated rat cardiomyocytes
exposed to an elevated [Ca
2?]o and a commonly used
b-adrenergic agonist–isoproterenol (ISO).
Materials and methods
Adult rat ventricular cardiomyocyte isolation
Adult male Wistar rats (200–300 g, 8–9 weeks in age,
n = 23) were euthanased using a schedule one procedure
in accordance with the UK Animals (Scientiﬁc Procedures)
Act 1986. Hearts were removed and perfused retrogradely
at 5 mL min
-1 (37C) with a modiﬁed isolation Krebs-
Henseleit (KH) solution for 4 min. The composition of the
isolation KH was (in mmol/L): NaCl (120), KCl (5.4),
HEPES (20), Na H2PO4 (0.52), MgCl26H2O (3.5), taurine
(20), creatine (10), glucose (11.1), pH 7.4 with NaOH. This
was followed by perfusion with KH containing 1 mg mL
-1
collagenase (type I, Worthington Biochemical, Lakewood,
NJ, USA), and 0.1 mg ml
-1 protease (type XIV, Sigma-
Aldrich, UK). After *6.0 min, enzyme was removed and
the heart perfused with nominally Ca
2?-free isolation KH
solution containing 1% BSA (Sigma-Aldrich, UK) for a
further 6.0 min. The left ventricular free wall was then cut
into strips and mixed to yield a single cell suspension. Cells
were maintained in either Ca
2?-free isolation KH solution
or 1.0 mmol/L Ca
2? (via stepwise increments) until use.
Field stimulation of intact cardiomyocytes
with simultaneous whole cell epi-ﬂuorescence
and shortening measurements
Intact cardiomyocytes in modiﬁed isolation KH solution
(above) were loaded with a Ca
2? sensitive ﬂuorophore
(5.0 lmol/L Fura-4F AM, Invitrogen, UK) by incubation
for *10 min. The incubation medium was removed and
the cells re-suspended in a second modiﬁed KH solution
with the following composition (in mmol/L): NaCl (140),
KCl (4.0), MgCl2 (1.0), HEPES (5.0), glucose (11.1), pH
7.4 with NaOH with 1.25 mmol/L [Ca
2?] added. Cells
were incubated for a further 30 min to ensure complete de-
esteriﬁcation. Cardiomyocytes were allowed to settle on a
coverslip, placed on a bath (Cell Microcontrols, Norfolk,
VA, USA) and super-fused with the same modiﬁed KH
solution at 37C. Cells were ﬁeld stimulated with 2 ms
duration voltage pulses delivered through parallel platinum
wires (stimulation voltage set to 1.5 times the threshold).
K201 (a gift from Aetas Pharma Co. Ltd., Japan) was
prepared at a stock concentration of 1.0 mmol/L in 10%
DMSO; the ﬁnal concentration of K201 in the perfusate
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control experiments were performed; all data obtained in
K201 were normalised to these timed controls. The Fura-
4F ﬂuorescence (340 and 380 nm excitation; R340/380nm)
was measured using a spinning wheel spectrophotometer
(Cairn Research Ltd., UK; sampling rate of 500 Hz) whilst
cellular shortening was measured using a video edge
detection system (IonOptix, Milton, MA, USA; sampling
rate of 200 Hz). Data were analysed ofﬂine. Fura-4F
ﬂuorescence ratio was converted to intracellular [Ca
2?]
([Ca
2?]i) as previously described [21]. Mean [Ca
2?]i and
cell shortening signals were obtained by averaging 12
steady state transients (Origin; Online resource I). The
mean minimum [Ca
2?]i was measured from a single point
at which [Ca
2?]i was at its lowest during the diastolic
period [see online resource I(b)]. Diastolic Ca
2? event
amplitude, the degree of spontaneous Ca
2? release, was
calculated from the minimum [Ca
2?]i to the peak diastolic
[Ca
2?]i reached during the diastolic period. Diastolic Ca
2?
events do not necessarily return to the minimum [Ca
2?]i
before the next action-potential stimulation. The [Ca
2?]i
immediately preceding the point of stimulation is therefore
termed as the pre-stimulus [Ca
2?]i (pre-stim). Pre-stim
[Ca
2?]i was subtracted from the stimulated [Ca
2?]i tran-
sient peak to determine stimulated Ca
2? transient ampli-
tude. Shortening data were expressed as percentage of
resting cell length (% RCL) where resting cell length was
taken at the quiescent cell length prior to commencement
of ﬁeld stimulation. Cell shortening parameters were
measured as described above for [Ca
2?]i and shown in
Online resource Ib.
Myoﬁlament Ca
2? sensitivity measurements
in intact cells
Intact cardiomyocytes in modiﬁed KH solution were
Fura-4F AM loaded and ﬁeld stimulated as above. Fluo-
rescence and cell shortening were assessed in three sub-
sets of experiments during perfusion with KH solution
containing: (a) a range of [Ca
2?]o (0.5–1.8 mmol/L),
(b) 1.8 mmol/L [Ca
2?]o in the presence of K201 (0.3, 1.0
and 3.0 lmol/L) and (c) 1.8 mmol/L [Ca
2?]o in the
presence of diltiazem (4.0 and 8.0 lmol/L, Sigma-
Aldrich, UK). Data obtained in KH solution with a
[Ca
2?]o of 1.8 mmol/L were obtained for each sub-set of
experiments (to account for any variation between cell
populations) and served as respective control groups.
Fura-4F ﬂuorescence was converted to [Ca
2?]i as above
and cell shortening amplitudes were expressed as a per-
centage of the shortening amplitude at a [Ca
2?]o of
1.8 mmol/L. An additional set of experiments in perme-
abilised cells directly assessed the effect of K201 on the
myoﬁlaments (Online resource II).
Simultaneous ﬁeld stimulation of intact cardiomyocytes
with confocal imaging
Intact cardiomyocytes in a modiﬁed KH solution were
loaded with Fluo-3AM and superfused with modiﬁed KH
(composition as above). Confocal line-scan images of ﬁeld
stimulated cardiomyocytes were recorded using a Radiance
2000 confocal system (BioRad, UK). Fluo-3 was excited at
488 nm (Kr laser) and measured [515 nm using epiﬂuo-
rescence optics of an inverted microscope with a 60X/1.2
NA water-immersion objective lens. Fluorescence was
acquired in line-scan mode at 2 ms line
-1; pixel dimension
was 0.3 lm (512 pixels/scan; zoom = 1.4) [2]. The scan-
ning laser line was orientated parallel with the long axis of
the cell and placed approximately equidistant between the
outer edge of the cell and the nucleus/nuclei to ensure the
nuclear area was not included in the scan line. Exact timing
of electrical stimulation was marked in the confocal image
by activating a light-emitting diode above the cell bath for
2 ms (i.e. duration of one line-scan), 8 ms before electrical
stimulation. Fluorescence data were expressed as a ratio of
the quiescent ﬂuorescence (F/F0). F/F0 measurements and
the number of initiation points/diastolic interval were cal-
culated from 15 s periods of line scan trace.
Data analysis and statistical procedures
Data were expressed as mean ± SEM. For Ca
2? transient
amplitude and Ca
2? wave parameters, comparisons were
performed by applying the paired Student’s t test. ANOVA
statistics with either a Tukey (Ca
2? transient and shorten-
ing parameters) or Dunnett (myoﬁlament sensitivity) post-
test were used in cases of multiple comparisons. Differ-
ences were considered signiﬁcant when P\0.05.
Results
Measurement of spontaneous diastolic events
in isolated ventricular cardiomyocytes
To gain an insight into the cellular mechanisms which
contribute to the beneﬁcial effect of K201 in a previously
published pharmacologically induced in vivo rat model of
diastolic dysfunction [14] isolated rat cells were perfused
with a modiﬁed KH solution containing the [Ca
2?]o and
additions shown in Fig. 1a. Cells were ﬁeld stimulated at
2.0 Hz to obtain a sufﬁcient length of time between stim-
ulations in which to characterise diastolic release events
during an elevated [Ca
2?]o and b-adrenergic stimulation.
When cells were perfused with 4.75 mmol/L [Ca
2?]o ?
150 nmol/L isoproterenol (referred to hereafter as ‘‘ISO’’),
the amplitude of diastolic rises of [Ca
2?]i was markedly
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2?]o alone (refer-
red to hereafter as ‘‘4.75’’) [73.5 ± 4.8 vs. 483 ±
103 nmol/L; 4.75 vs. ISO: n = 8, P\0.05; Fig. 1b(i vs.
ii) top panel and c(i)]. These diastolic Ca
2? events con-
sistently occurred in parallel with diastolic contractile
events (Fig. 1b(i vs. ii) bottom panel and d(i)) and were
similar to the diastolic rises of intra-ventricular pressure
observed in vivo using a similar protocol [14]. When
compared to DMSO vehicle time controls, perfusion with
4.75 mmol/L [Ca
2?]o ? 150 nmol/L isoproterenol ?
1.0 lmol/L K201 for 4 min (referred to hereafter as
‘‘K201’’) resulted in a cell-to-cell variable response on
diastolic Ca
2? events. K201 signiﬁcantly reduced the
magnitude of diastolic Ca
2? events in all cells tested
(100%) and, in *50% cells, these were completely abol-
ished (Fig. 1b(iii)). The mean response to K201 was to
signiﬁcantly reduce both the amplitudes of diastolic Ca
2?
events [483 ± 103 vs. 154 ± 46 nmol/L; ISO vs. K201:
n = 8, P\0.05; Fig. 1c(i)] and diastolic contractile
events [4.90 ± 0.73–0.77 ± 0.33% RCL; ISO vs. K201:
n = 8, P\0.05; Fig. 1d(i)].
Application of 150 nmol/L ISO resulted in a signiﬁcant
increase in the mean minimum [Ca
2?]i compared to
4.75 mmol/L [Ca
2?]o alone (60.9 ± 1.7 vs. 159 ±
33.0 nmol/L; 4.75 vs. ISO: n = 8, P\0.05; data not
shown). Subsequent perfusion with K201 did not
Fig. 1 Effect of 1.0 lmol/L
K201 on [Ca
2?]i and cell
shortening a perfusion protocol.
b records of [Ca
2?]i (upper) and
cell length (lower) at points
denoted in a. c mean ± SEM
values of for (i) diastolic event
free [Ca
2?]i amplitude, (ii) pre-
stimulus free [Ca
2?]i and (iii)
peak free [Ca
2?]i of stimulated
transient. d mean ± SEM
values of cell shortening for
(i) diastolic event amplitude,
(ii) pre-stimulus and (iii) peak
of stimulated transient. Black
bars, 4.75: 4.75 mmol/L
[Ca
2?]o; White bars, ISO:
4.75 mmol/L
[Ca
2?]o ? 150 nmol/L ISO;
Grey bars, K201: 4.75 mmol/L
[Ca
2?]o ? 150 nmol/L
ISO ? 1.0 lmol/L K201;
n = 8, *P\0.05
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123signiﬁcantly alter the mean minimum [Ca
2?]i (159 ± 33.0
vs. 120 ± 24.9 nmol/L; ISO vs. K201: n = 8, P[0.05;
data not shown).
Measurement of the peak stimulated event in isolated
ventricular cardiomyocytes
The mean peak of the stimulated [Ca
2?]i transient was
signiﬁcantly reduced by K201 [1,900 ± 367 vs. 1,350 ±
260 nmol/L; ISO vs. K201: n = 8, P\0.05; Fig. 1c(iii)]
as was the mean pre-stimulus [Ca
2?]i [411 ± 40 vs.
216 ± 52 nmol/L; ISO vs. K201: n = 8, P\0.05;
Fig. 1c(ii)]. In contrast, there was no signiﬁcant alteration
in either the mean peak of the stimulated cell shortening
[15.04 ± 1.49 vs. 13.60 ± 1.52% RCL; ISO vs. K201;
n = 8, P[0.05; Fig. 1d(iii)], mean pre-stimulus cell
shortening [(5.89 ± 0.84 vs. 6.74 ± 1.12% RCL; ISO vs.
K201; n = 8, P[0.05; Fig. 1d(ii)] or the mean minimum
cell shortening (3.23 ± 0.47 vs. 3.43 ± 0.47% RCL; ISO
vs. K201; n = 8, P[0.05; data not shown) following
application of K201.
Separate voltage clamp measurements on cells under
identical conditions (including the presence of an elevated
[Ca
2?]o) showed only a small decrease in L-type Ca
2?
channel amplitude in response to 1.0 lmol/L K201
(95.6 ± 4.4% of timed control level—see Online resource
III).
The effect of K201 on the overall electrical activity of
ventricular cells was assessed from ECG measurements on
isolated Langendorff perfused whole hearts (see Online
resource IV). These revealed no signiﬁcant differences in
QT interval at a ﬁxed stimulus rate suggesting no major
change in action potential duration in rat hearts exposed to
1.0 lmol/L K201.
Effects of K201 on myoﬁlament Ca
2? sensitivity
An assessment of the ability of K201 to alter myoﬁlament
Ca
2? sensitivity was made as this was a previously pro-
posed mechanism to explain the in vivo improvement of
function in the rat [14]. b-adrenergic stimulation alters the
Ca
2? sensitivity of the myoﬁlaments and an elevated Ca
2?
concentration (i.e. 4.75 mmol/L [Ca
2?]o) leads to the
production of diastolic contractile events (which can affect
the amplitude of the subsequent Ca
2? transient) therefore,
these experiments were performed in the absence of
b-adrenergic stimulation and at lower [Ca
2?]o to ensure
that diastolic Ca
2? events did not occur. Simultaneous
measurements of [Ca
2?]i and cell shortening were used to
establish the relationship between Ca
2? transient parame-
ters and cell shortening amplitudes in response to varying
[Ca
2?]o. Cells were ﬁeld stimulated and perfused with
modiﬁed KH solutions containing a range of [Ca
2?]o from
1.8 to 0.5 mmol/L. As shown in Fig. 2a, reducing [Ca
2?]o
from 1.8 mmol/L (control) to 0.5 mmol/L resulted in a
signiﬁcant decrease in Ca
2? transient peak [Ca
2?]i [617 ±
25 vs. 180 ± 6 nmol/L; 1.8 (control) vs. 0.5 mmol/L
[Ca
2?]o: n = 14, P\0.05] and minimum [Ca
2?]i
[140 ± 4v s . 81 ± 2 nmol/L; 1.8 (control) vs. 0.5 mmol/L
[Ca
2?]o: n = 14, P\0.05]. This was accompanied by an
*90% reduction in cell shortening amplitude [100.0 vs.
9.28 ± 3.57%; 1.8 mmol/L (control) vs. 0.5 mmol/L
[Ca
2?]o: n = 14, P\0.05].
In a second set of experiments, the effect of a range of
concentrations of K201 (0.3–3.0 lmol/L) on Ca
2? transient
parameters and cell shortening amplitudes was examined at
a constant [Ca
2?]o (1.8 mmol/L [Ca
2?]i). Perfusion with
K201 (0.3–3 lmol/L) led to a dose-dependent decrease in
Ca
2? transient peak and minimum [Ca
2?]i and cell short-
ening amplitude (Fig. 2b). Addition of 1.0 lmol/L K201
(red symbols) signiﬁcantly reduced Ca
2? transient peak
[Ca
2?]i [640 ± 16 vs. 409 ± 13 nmol/L; 1.8 mmol/L
[Ca
2?]o (control, grey symbols) vs. 1.8 mmol/L [Ca
2?]o ?
1.0 lmol/L K201: n = 24, P\0.05]. Similarly, 1.0 lmol/
L K201 reduced cell shortening amplitude by *53%
[100.0 vs. 47.25 ± 3.99%; 1.8 mmol/L [Ca
2?]o (control,
grey symbol) vs. 1.8 mmol/L [Ca
2?]o ? 1.0 lmol/L K201:
n = 24, P\0.05 vs. control].
To determine the effect of K201 on the relationship
between Ca
2? transient parameters and cell shortening
amplitude shown in Fig. 2a, Ca
2? transient amplitudes at
each K201 concentration were matched to those mea-
sured in Ca
2? alone by extrapolation of the K201 Ca
2?
transient peak and minimum points (example for
1.0 lmol/L K201 is demonstrated by horizontal red
dotted lines, Fig. 2b). Experimentally derived cell short-
ening amplitudes obtained in 1.8 mmol/L [Ca
2?]o and
each concentration of K201 were then plotted at the
corresponding [Ca
2?]o value (e.g. for 1.0 lmol/L K201,
vertical red dotted line). As seen in Fig. 2b, the rela-
tionship between Ca
2? transient parameters and cell
shortening in K201 is the same as that for varying
[Ca
2?]o alone. For example, the mean Ca
2? transient
amplitude in 1.0 lmol/L K201 (297 ± 16 nmol/L) pre-
dicts a cell shortening amplitude of 49.1% of control
which was conﬁrmed by the experimentally measured
value of 47.2 ± 4.0% in 1.0 lmol/L K201.
Using the relationship between Ca
2? transient parame-
ters and cell shortening amplitude derived when varying
[Ca
2?]o alone (Fig. 2a), it was observed that a Ca
2? tran-
sient amplitude equivalent to that of 1.0 lmol/L K201 in
1.8 mmol/L [Ca
2?]o (297 ± 16 nmol/L) was produced by
perfusion with [Ca
2?]o of 1.1 mmol/L (without K201). To
verify the above negative result of K201 on myoﬁlament
Ca
2? sensitivity, these two solutions were sequentially
perfused onto a separate sub-set of cells to directly assess
Basic Res Cardiol (2011) 106:1009–1022 1013
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2? transient
amplitudes. Figure 2c shows mean data for [Ca
2?]i and cell
shortening obtained in response to 1.0 lmol/L K201 in
1.8 mmol/L Ca
2? expressed relative to that at 1.1 mmol/L
[Ca
2?]o alone (100%, without K201; dashed line). The
mean data show that at equivalent Ca
2? transient ampli-
tudes, K201 does not signiﬁcantly alter cell shortening
(transient amplitude: 100.48 ± 0.85% of control; shorten-
ing amplitude: 99.53 ± 1.95% of control; n = 7, P[0.05
for each).
To expand this ﬁnding, a third set of experiments were
performed utilising diltiazem as a tool to alter Ca
2? tran-
sient parameters to a similar degree as reducing [Ca
2?]o
alone. Diltiazem (4.0 and 8.0 lmol/L) caused a dose-
dependent decrease in transient peak and minimum [Ca
2?]i
(Fig. 2d). Equivalent Ca
2? transient amplitudes in diltia-
zem were matched to the relationship derived in Ca
2?
alone (in Fig. 2a) and cell shortening amplitudes were
plotted as before. At equivalent Ca
2? transient amplitudes,
cell shortening in the presence of diltiazem was not sig-
niﬁcantly different from the levels predicted by altering
[Ca
2?]o alone.
Effects of K201 on SR function
Following 1.5 min of 4.75 mmol/L [Ca
2?]o ? 150 nmol/L
ISO then 4.0 min perfusion with or without 1.0 lmol/L
K201, rapid application of 10.0 mmol/L caffeine was used
to asses SR Ca
2? content (Fig. 3a(i)). Perfusion with K201
resulted in no signiﬁcant alteration of SR free Ca
2? content
as determined by the mean amplitude of the caffeine-
induced Ca
2? transient [1,310 ± 230 vs. 1,400 ±
260 nmol/L; 4.75 mmol/L ISO vs. K201; n = 8, P[0.05;
Fig. 3a(ii)]. The rate of decline of the caffeine-induced
transients is a measure of the rate of sarcolemmal Ca
2?
extrusion, these rates were not altered following K201
(1.35 ± 0.15 vs. 1.21 ± 0.15 lmol/L s
-1; ISO vs. K201;
n = 8, P[0.05; data not shown).
Given the dramatic reduction in the amplitude of dia-
stolic Ca
2? release events by K201, the [Ca
2?]i immedi-
ately preceding the stimulus (pre-stim) was lower after
K201 (see Fig. 1c(ii)). The consequences of this alteration
in diastolic Ca
2? level at the point of action potential-
induced Ca
2? release must be considered when assessing
the effect of K201 on the Ca
2? transient amplitude. To
Fig. 2 Effect of 1.0 lmol/L
K201 on myoﬁlament Ca
2?
sensitivity a relationship
between free Ca
2? transient
parameters (peak and minimum)
and cell shortening amplitudes
(% shortening) in response to
varying external [Ca
2?]
(n = 14, *P\0.05
vs.1.8 mmol/L for each). b as in
a with additional points
obtained in 1.8 mmol/L external
[Ca
2?] and K201 (0.3, 1.0 and
3.0 lmol/L; n = 24, P\0.05
for shortening amplitudes at all
concentrations vs. 1.8 mmol/L,
P\0.05 for peak [Ca
2?]i at 1
and 3 lmol/L K201 vs.
1.8 mmol/L). c mean ± SEM
values for percentage change in
amplitude of free [Ca
2?]i and
shortening amplitudes in
1.0 lmol/L K201 expressed
relative to control in 1.1 mmol/
L external Ca
2? (100%; n = 7).
d as in a with additional points
obtained in 1.8 mmol/L external
[Ca
2?] and diltiazem (4.0 and
8.0 lmol/L n = 8, P\0.05 for
shortening amplitudes and peak
[Ca
2?]i at both concentrations
vs. 1.8 mmol/L and for
minimum [Ca
2?]i at 8.0 lmol/L
diltiazem vs. 1.8 mmol/L)
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123allow for varying degrees of intracellular buffering of
SR release under these two conditions, mean traces were
converted to total cellular [Ca
2?] using previously
reported intracellular buffer concentrations and afﬁnities
(Fig. 3b(i, ii), [8]). The Ca
2? transient amplitude was mea-
sured by subtracting the pre-stim from the peak of the
stimulated transient for the average signals convertedto free
[Ca
2?] and total [Ca
2?]. This analysis revealed that whilst
K201 produced a signiﬁcant reduction in the amplitude of
thefreeCa
2?transient[1.32 ± 0.26vs.1.05 ± 0.21 lmol/L;
ISO vs. K201: n = 11, P\0.05; Fig. 3c(i)] there was a sig-
niﬁcant increase in the amplitude of the total Ca
2? transient
[76.8 ± 6.3 vs. 99.8 ± 8.5 lmol/L; ISO vs. K201: n = 11,
P\0.05; Fig. 3c(ii)]. Conversion of the caffeine-induced
Ca
2? t r a n s i e n tt ot o t a l[ C a
2?]i showed no signiﬁcant differ-
ence between SR content in ISO and K201 (Fig. 3c(iii)).
Characterisation of the stimulated Ca
2? transients
shown in Fig. 1 revealed that whilst 1.0 lmol/L K201 did
not alter the maximum rate of rise of the stimulated Ca
2?
transient it signiﬁcantly decreased both the maximum rate
of fall [4.3 9 10
-5 ± 1.1 9 10
-5 vs. 2.4 9 10
-5 ±
6.4 9 10
-6 Ms
-1; ISO vs. K201: n = 8, P\0.05; Online
resource V(a)] and the rate of fall at 500 nmol/L
[Ca
2?]i [1.8 9 10
-5 ± 2.2 9 10
-6 vs. 1.1 9 10
-5 ±
1.3 9 10
-6 Ms
-1; ISO vs. K201: n = 8, P\0.05; Online
resource V (b and c), respectively]. Separate direct mea-
surements of the effect of 1.0 lmol/L K201 on SERCA
activity showed no signiﬁcant inhibition of the rate con-
stant of decay of free [Ca
2?]i [index of SERCA function in
a permeabilised cell assay as described in Online resource
Materials, Online resource V(d)]. While the effect of K201
was not apparent at 1.0 lmol/L, at the higher concentration
Fig. 3 Effect of 1.0 lmol/L K201 on Ca
2? transient amplitude and
SR Ca
2? content a (i) typical records of free [Ca
2?]i in a cell perfused
with 4.75 mmol/L [Ca
2?]o ? 150 nmol/L ISO then 1 lmol/L K201
with subsequent caffeine application (arrow); (ii) mean ± S.E.M.
values of caffeine-induced free Ca
2? transient amplitude (n = 8).
b Average transient in free Ca
2? (black trace) and total Ca
2? (grey
trace) in the presence of (i) ISO: 4.75 mmol/L [Ca
2?]o ? 150 nmol/
L ISO and (ii) ISO ? K201: 4.75 mmol/L [Ca
2?]o ? 150 nmol/L
ISO ? 1.0 lmol/L K201; dashed lines denote stimulus mark.
c mean ± SEM values of (i) free Ca
2? transient amplitude
(n = 11) and (ii) total Ca
2? transient amplitude (n = 11) both
measured from the peak Ca
2? minus pre-stim Ca
2? of their respective
averaged traces; (iii) caffeine-induced total Ca
2? transient amplitude.
(n = 8). White bars, ISO: 4.75 mmol/L [Ca
2?]o ? 150 nmol/L
ISO, Grey bars, K201: 4.75 mmol/L [Ca
2?]o ? 150 nmol/L
ISO ? 1.0 lmol/L K201; *P\0.05
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123of 10.0 lmol/L, the rate constant of decay was signiﬁcantly
reduced to 73.9 ± 2.5% [Online resource V(e), n = 4,
P\0.05].
Confocal measurements of diastolic Ca
2? events
during b-adrenergic stimulation
To visualise the effect of K201 on individual diastolic Ca
2?
release events at an enhanced spatiotemporal resolution, a
set of experiments was performed using confocal imaging
of rat cardiomyocytes perfused with the same [Ca
2?]o and
additions as in Fig. 1 (Fig. 4a). Line scan confocal imaging
revealed a synchronous rise of [Ca
2?]i along the length of
the scan line at each stimulation point (Fig. 4b; red dashed
lines denote stimulation mark). Upon perfusion with
4.75 mmol/L [Ca
2?]o ? 150 nmol/L ISO, spontaneous
diastolic Ca
2? events were visualised in the line scan
(Fig. 4b(ii) vs. b(i) top panels) and corresponding ﬂuores-
cence intensity proﬁles (Fig. 4b(ii) vs. b(i) bottom panels).
Diastolic Ca
2? events were initiated at discrete points
along the scan line (Fig. 4b(ii) top panel) and then propa-
gated along the cell length identifying these diastolic
events as being the result of multiple Ca
2? waves. Initia-
tion points of the Ca
2? waves were identiﬁed on the basis
of evidence from the line scan image of propagation away
from a separate site. The number of initiation points which
Fig. 4 Characterisation of
diastolic Ca
2? release events
a perfusion protocol (upper) and
typical records of Fluo-3
ﬂuorescence (lower). b Typical
line scan images (upper) and
corresponding ﬂuorescence
proﬁles (lower) in the presence
of (i) 4.75 mmol/L [Ca
2?]o,( ii)
4.75 mmol/L
[Ca
2?]o ? 150 nmol/L ISO and
(iii) 4.75 mmol/
L[Ca
2?]o ? 150 nmol/L
ISO ? 1.0 lmol/L K201;
dashed lines (red) represent
stimulus mark, circles represent
wave initiation points.
c mean ± SEM values of
(i) number of wave initiation
points/diastolic interval and (ii)
ﬂuorescence signals measured
at the peak and at 950 ms post
stimulation. White bars, ISO:
4.75 mmol/L
[Ca
2?]o ? 150 nmol/L ISO;
Grey bars, ISO ? K201:
4.75 mmol/L
[Ca
2?]o ? 150 nmol/L
ISO ? 1.0 lmol/L K201;
n = 11, *P\0.05
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2? waves was markedly increased when ISO was
added to the perfusing solution and typically resulted in
multiple waves in the diastolic interval (Fig. 4b(ii) top
panel). Application of1.0 lmol/L K201 caused asigniﬁcant
reduction in the frequency of diastolic events (12.45 ± 1.36
vs. 7.55 ± 1.53 diastolic events/15 s period; ISO vs. K201:
n = 11, P\0.05—data not shown) and, as illustrated in
Fig. 4b(iii) and c(i), a signiﬁcant reduction in the initiation
points/diastolic interval in the remaining diastolic Ca
2?
release events [1.43 ± 0.09 vs. 1.02 ± 0.02; ISO vs. K201:
n = 11, P\0.05; Fig. 4c(i)]. This was accompanied by no
signiﬁcant change in stimulated transient peak ﬂuorescence
but a signiﬁcant reduction in the ﬂuorescence measured at
950 ms post stimulation compared to control [2.33 ± 0.20
vs. 1.48 ± 0.15 F/F0; ISO vs. K201: n = 11, P\0.05;
Fig. 4c(ii)]. Measurements of Ca
2? spark events during the
diastolicperiodrevealedasigniﬁcantdecreaseinCa
2?spark
amplitude (3.24 ± 0.18 vs. 2.84 ± 0.16; ISO vs. K201:
n = 416 control sparks and n = 183 K201 sparks,
P\0.05) and a trend towards a decrease in Ca
2? spark
frequency (see Online resource VI).
Confocal measurements of diastolic Ca
2? events
during elevated [Ca
2?]o
A sub-set of cells exhibited a propensity to produce dia-
stolic Ca
2? events when exposed to 4.75 mmol/L [Ca
2?]o
without ISO (Fig. 5a). Confocal images obtained from
these cells showed a synchronous rise of [Ca
2?]i at each
stimulation point and multiple waves originating at various
initiation points during the diastolic interval (Fig. 5b(i)).
Application of 1.0 lmol/L K201 without ISO (referred to
Fig. 5 Characterisation of
diastolic Ca
2? release events in
the absence of ISO a perfusion
protocol (upper) and typical
records of Fuo-3 ﬂuorescence
(lower). b typical line scan
images (upper) and
corresponding ﬂuorescence
proﬁles (lower) in the presence
of (i) 4.75 mmol/L [Ca
2?]o and
(ii) 4.75 mmol/L
[Ca
2?]o ? 1.0 lmol/L K201;
dashed lines (red) represent
stimulus mark, circles represent
wave initiation points.
c mean ± SEM values of
(i) number of wave initiation
points/diastolic interval and (ii)
ﬂuorescence signals measured
at the peak and at 950 ms post
stimulation. White bars, 4.75:
4.75 mmol/L [Ca
2?]o; Grey
bars, 4.75 ? K201: 4.75 mmol/
L [Ca
2?]o ? 1.0 lmol/L K201;
n = 4, *P\0.05
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123hereafter as 4.75 ? K201) markedly reduced the frequency
of these initiation points/diastolic interval [1.33 ± 0.13 vs.
1.03 ± 0.02; 4.75 vs. 4.75 ? K201: n = 4, P\0.05;
Fig. 5b(ii), c(i)] along with a signiﬁcant decrease in the
diastolic ﬂuorescence measured at 950 ms post stimulation
compared to 4.75 mmol/L [Ca
2?]o without K201
[2.33 ± 0.39 vs. 1.15 ± 0.07 F/Fo; 4.75 vs. 4.75 ? K201:
n = 4, P\0.05; Fig. 5c(ii)]. No signiﬁcant change in
stimulated transient peak ﬂuorescence was observed.
Confocal measurements of Ca
2? wave initiation points
and diastolic Ca
2? event amplitude
To examine the relationship between the number of initia-
tion points per diastolic event and corresponding diastolic
event amplitude, the confocal images of a number of cells
(n = 8) perfused with 4.75 mmol/L [Ca
2?]o and ISO were
examined as in Fig. 6a(i–iii) with respective ﬂuorescence
intensityproﬁles (Fig. 6btop–bottom). Number of initiation
points (highlighted by red circles—Fig. 6a) per diastolic
event was plotted against the amplitude of that event
(Fig. 6c). The mean data showed a positive correlation
between the two parameters with signiﬁcant differences
between1,2and3initiationpoints(1.06 ± 0.1,1.87 ± 0.1,
2.58 ± 0.26 F/F0; P\0.05; Fig. 6c), respectively.
Discussion
We have provided for the ﬁrst time a detailed character-
isation of the effects of K201 on the stimulated Ca
2?
transient, spontaneous diastolic SR mediated Ca
2? release
and contractile events during application of b-adrenergic
stimulation and an elevated [Ca
2?]o in rat cardiomyocytes.
Our main ﬁndings are: (a) K201 has no effect on stimulated
cell shortening but signiﬁcantly reduces spontaneous dia-
stolic contractile events induced by elevated Ca
2? loading,
(b) K201 produces a small but signiﬁcant reduction in
stimulated free Ca
2? transient amplitude and signiﬁcantly
reduces spontaneous Ca
2? release events with no alteration
in SR Ca
2? content, (c) when intracellular buffering is
taken into account, K201 produces a signiﬁcant increase in
total Ca
2? transient amplitude, (d) K201 had no effect on
myoﬁlament Ca
2? sensitivity thereby discounting this
previously proposed mechanism to explain the in vivo
improvement of function in the rat [14], (e) 1.0 lmol/L
K201 does not inhibit SERCA in rat cardiomyocytes
(which is in contrast to the effect in rabbit [18]) and
(f) spontaneous diastolic Ca
2? events occurred in the form
of multiple propagating Ca
2? waves (each with an initiat-
ing point) and that K201 acts to reduce both the event
frequency and number of initiation points per diastolic
event.
Comparison between the effect of K201 on diastolic
contractions in vivo and in isolated cardiomyocytes
A previous study has demonstrated that in vivo application
of a b-adrenergic agonist and an elevated [Ca
2?]o led to the
production of diastolic contractions resulting in a raised
intra-ventricular pressure measured at the R wave [14].
This pharmacological intervention resulted in a model of
severe acute diastolic dysfunction without a signiﬁcant
change in systolic peak pressure. Application of 1.0 lmol/
L K201 in vivo reduced the occurrence of the diastolic
contractures and signiﬁcantly reduced the mean intra-ven-
tricular pressure measured at the R wave with no signiﬁ-
cant alteration of the peak pressure. With the caveat that
detailed comparison of contractile function between iso-
lated cardiomyocyte and whole heart experiments is
Fig. 6 Characterisation of Ca
2? wave initiation points a (i–iv) typical
line scan images with varying numbers of initiation points; red lines
and circles denote stimulus mark and initiation points, respectively.
b (top to bottom): ﬂuorescence intensity proﬁles corresponding to the
images in a; arrows represent the time of stimulation. c mean ± SEM
data showing the relationship between diastolic Ca
2? event initiation
points and diastolic Ca
2? event amplitude taken from 8 cells in Fig. 4
(1, 2 and 3 initiation points, n = 42, 30 and 6 diastolic Ca
2? events,
respectively, *P\0.05)
1018 Basic Res Cardiol (2011) 106:1009–1022
123problematic, the aforementioned effect of K201 on the
mechanical function of the whole rat heart demonstrates
some similarities to shortening measurements in isolated
rat cardiomyocytes performed in this study (Fig. 1). In the
present study, b-adrenergic stimulation of ventricular
cardiomyocytes perfused with an elevated [Ca
2?]o also led
to the production of spontaneous diastolic cellular con-
tractions. The amplitude of the spontaneous diastolic con-
tractures was signiﬁcantly reduced by K201 (to *16% of
control) with no alteration of the stimulated shortening
amplitude. One difference between the in vivo rat study
and the isolated cardiomyocyte experiments is the response
of the cells in the current study with elevated [Ca
2?]o to
ISO, which resulted in a positive ionotropy (Fig. 1d(iii)). A
trend to positive inotropy also existed within the in vivo
model (reﬂected by the increase in left ventricular pressure)
after 25 min of an elevated [Ca
2?]o and b-adrenergic
stimulation but this did not reach signiﬁcance. Reasons for
this discrepancy include the fact that the single cardio-
myocytes were (a) only exposed to b-adrenergic stimula-
tion and an elevated [Ca
2?]i for *5.0 min and (b) ﬁeld
stimulated (paced) and therefore not affected by the
changes in heart rate which accompany an in vivo
response.
The relationship between the stimulated Ca
2? transient
and cell shortening amplitude
The current data reveal for the ﬁrst time the relationship
between the effect of K201 on stimulated Ca
2? transient
amplitude together with the degree of cell shortening. The
results demonstrate that although 1.0 lmol/L K201 sig-
niﬁcantly reduced the stimulated free Ca
2? transient
amplitude by 16.1% [P\0.05; Fig. 3a(ii)], the stimulated
shortening amplitude was not signiﬁcantly affected. No
data exist in the literature as to the effect of K201 on the
myoﬁlament sensitivity to [Ca
2?]i. To investigate this, the
relationship between Ca
2? transient amplitude and degree
of cell shortening was determined by lowering [Ca
2?]o to
various levels (Fig. 2). This relationship was unaltered in
the presence of a range of K201 concentrations or an
alternative benzothiazepine derivative (diltiazem) thereby
demonstrating that K201 does not alter the sensitivity of
the myoﬁlaments under these conditions. Further veriﬁca-
tion of this was obtained via direct myoﬁlament measure-
ments performed in permeabilised rat ventricular
cardiomyocytes at a free [Ca
2?]i of 840 nmol/L (Online
resource II) and conﬁrmed at 375 nmol/L (data not shown).
The latter concentration is equivalent to the mean [Ca
2?]i
observed during perfusion of 1.0 lmol/L K201 during b-
adrenergic stimulation and an elevated [Ca
2?]o
(359 ± 43.9; n = 8; Fig. 1). Thus, the absence of a nega-
tive inotropic effect of K201 may be based on the
non-linear relationship between peak [Ca
2?]i and shortening
under conditions of Ca
2? overload. It is not clear why K201
did not alter mean minimum [Ca
2?]i; this may reﬂect the
lack of effect of K201 on sarcolemmal extrusion as previ-
ously reported [18].
The effect of K201 on the SR Ca
2? content
Previous studies have attributed the beneﬁcial effect of
K201 on diastolic cardiac function to the ability of K201 to
ensure maximal binding of FKBP12.6 to the RyR2 thus
reducing the open probability of RyR2 [26]. The resultant
effect would be to prevent diastolic Ca
2? release and
subsequently to reduce arrhythmias and diastolic contrac-
tions. Venetucci et al. [25] have demonstrated in rat
cardiomyocytes that the sole inhibitory effect on RyR2 by
tetracaine (a drug which decreases the open probability of
RyR2) can lead to inhibition of diastolic Ca
2? events
between depolarisations but leads to an increase in the
amplitude of systolic Ca
2? transient and SR Ca
2? content
[4, 25]. The current study observed signiﬁcant inhibition of
diastolic Ca
2? spark activity by 1.0 lmol/L K201 sup-
porting the concept that K201 reduces the activity of RyR2
but no signiﬁcant difference in SR content was observed.
However, due to the cell-to-cell variability in the caffeine
response it is acknowledged that the measurements in the
current study may have been unable to discriminate a
*10–12% change in SR Ca
2? content. Despite this limi-
tation, it should be recognised that K201 is not the only
drug which demonstrates inhibition of RyR2 without a
concomitant increase in SR Ca
2? content. Flecainide has
been reported to reduce Ca
2? wave amplitude in permea-
bilised rat cardiomyocytes without alteration in the SR
Ca
2? content or SERCA activity. This is thought to have
been achieved by inhibition of RyR2 via an open state
block; under these circumstances comparable leak is
achieved via signiﬁcantly higher spark rates despite a sig-
niﬁcantly reduced ‘‘spark mass’’ [7].
The effect of K201 on the Ca
2? transient amplitude
K201 has been shown to prevent diastolic dysfunction and
improve systolic function during Ca
2? overload conditions
in terminally failing human myocardial preparations [24].
In contrast to the current study, no direct measurements of
the Ca
2? transient or [Ca
2?]i were performed. In another
previous study by the authors, on this occasion in rabbit
cardiomyocytes, the amplitude of depolarisation-induced
Ca
2? transients was reduced by 1.0 lmol/L K201 but this
did not reach signiﬁcance [18]. Cellular shortening mea-
surements were not reported in this previous work. The
current study permits further insight into the effects of
K201 using a ﬂuorophore (Fura 4F AM) with a lower
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2?]
transient with more accuracy [28]. These novel data sug-
gest that the action potential-induced free Ca
2? transients
demonstrate a small but signiﬁcant reduction in amplitude
in response to 1.0 lmol/L K201. These changes occurred
in the absence of major changes in ventricular electro-
physiology (ECG recordings; Online resource IV) or the
activity of common Ca
2? handling proteins, e.g. SERCA or
NCX (see Online Resource V). In particular, 1.0 lmol/L
K201 caused only a small decrease (*5%) in ICa ampli-
tude in the presence of an elevated [Ca
2?]o. This contrasts
with a previous study which showed a reduction of ICa peak
by 22% in rat cardiomyocytes [10], but is similar to the
*3% reduction observed in rabbit cardiomyocytes [18].
This slight reduction in ICa (*5%) would not be expected
to cause a signiﬁcant ([5%) change in Ca
2? transient
amplitude [9]. Superﬁcially, it would appear difﬁcult to
reconcile the absence of the effects of K201 on SR Ca
2?
content and ICa with the reduction in the peak of the
stimulated free Ca
2? transient. Particularly, since K201
was very effective in inhibiting spontaneous diastolic
Ca
2? release which should result in more Ca
2? being
available for release on the subsequent stimulus. The
reconciliation of these data comes when allowance is
made for the intracellular buffering which, as shown by
previous studies [8], is highly nonlinear over the range of
[Ca
2?]i measured in this study (*75–2,000 nmol/L).
Using the values of reported intracellular buffer concen-
trations and afﬁnities, the free [Ca
2?]i in this study were
converted to total cellular [Ca
2?]i. On this basis, the
amplitude of the Ca
2? transient (peak-pre-stim) when
expressed as total [Ca
2?]i indicates that on addition of
K201, the amount of Ca
2? release from the SR increased
(to *140% of control). This was not observed in terms of
free [Ca
2?]i because although more SR Ca
2? appeared to
be released after K201, the cellular buffer value was
higher resulting in a decreased peak systolic Ca
2? level.
Increased Ca
2? released from the SR on abolition of
spontaneous Ca
2? release is consistent with studies by
Venetucci et al. [25] who also reported increased SR
Ca
2? content on abolition of Ca
2? waves. This was not
evident from this study, but the variability of the data
would prevent increases of SR content of *10% being
detected; an increase in SR Ca
2? content as small as 10%
would be sufﬁcient to explain an increase of SR Ca
2?
release of *140% [23].
Other contributing factors which were not investigated
include alteration in the intracellular [Na
?]i. Future work
using the voltage clamp technique and monitoring of
intracellular [Na
?] i may uncover to what degree K201 is
able to alter the balance between Ca
2? inﬂux and efﬂux
and control for certain parameters which are not achievable
with the ﬁeld stimulation technique.
Confocal imaging reveals characteristics of diastolic
Ca
2? events
SR mediated Ca
2? release occurs via clusters of ryanodine
receptors. During diastole this occurs in the form of either
localised (Ca
2? sparks) or propagating whole cell Ca
2?
release (Ca
2? waves). Ca
2? waves are recognised as events
which could potentially lead to delayed after depolarisa-
tions (DADs) and triggered arrhythmias. A DAD occurs
when a transient inward current is produced upon extrusion
of SR-mediated diastolic Ca
2? via NCX. The ability of this
inward current to generate a DAD is, amongst other fac-
tors, dependent upon the size of the Ca
2? wave and the
inward current generated [19]. While there is an established
link between Ca
2? waves and electrical abnormalities, the
link between Ca
2? waves and mechanical dysfunction is
less clear. To ascertain the spatiotemporal properties of
the spontaneous diastolic Ca
2? release events, confocal
microscopy of ventricular cardiomyocytes was employed
using a similar protocol to that in Fig. 1. The experiments
revealed that the diastolic events were predominantly in the
form of propagating Ca
2? waves (Figs. 4, 5), which were
signiﬁcantly reduced in frequency and amplitude by
1.0 lmol/L K201. Characterisation of these events
revealed multiple initiating points, the number of which
was reduced upon application of 1.0 lmol/L K201. Thus,
whilst K201 acts to signiﬁcantly reduce the probability of
spontaneous diastolic events (by *50%) it also acts to
modulate the characteristics of the remaining events. The
signiﬁcance of the transition in the latter is illustrated in
Fig. 6. Diastolic Ca
2? events with multiple initiation points
(Fig. 6a(iii vs. ii)) tend towards being more synchronous in
activation (similar to the stimulated Ca
2? transient (Fig. 6a
(i)).Analysisofthewholecellﬂuorescence(Fig. 6b)reveals
that the larger number of initiation points results in a larger
amplitude of spontaneously released Ca
2? from the SR
(Fig. 6b (bottom)) and hence may increase the propensity to
generate a transient inward current. This is summarised in
the mean data presented in Fig. 6c, which demonstrate that
for every extra initiation point per diastolic Ca
2? event
during a short diastolic interval, the amplitude of the global
Ca
2? release increases by *1.8 times. Conversely, a
reduction in the number of these initiation points (Fig. 6b
(middle)) would be expected to lead to a reduction in Ca
2?
available for extrusion at any one time by NCX. An insight
intotheneteffectofthisresponsetoK201inamulti-cellular
preparationcanbeseen inthe averaged traces of[Ca
2?]iand
contraction (Online Resource Ia).
Synchronicity of initiation points in the ISO data set
(Fig. 4) was measured using the time between the ﬁrst and
last initiation point in each diastolic interval. This value
wasthencorrelatedwiththeCa
2?sparkfrequencyinthatcell.
In cells with low spark frequency (6.0 ± 1.1/100 lm/s), the
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the ﬁrst and last wave in a diastolic interval. In cells with a
much higher spark frequency (35.4 ± 1.1/100 lm/s), the
initiation points were on average 69.4 ± 7.3 ms between
the ﬁrst and last wave in a diastolic interval. This proved to
be a signiﬁcant correlation (P\0.05). In these two sub-
groups, Ca
2? spark amplitude was, however, not signiﬁ-
cantly different. Therefore, while the action of K201 to
reduce Ca
2? spark frequency (albeit not signiﬁcantly, see
online resource VI) may lead to a reduction in the syn-
chronicity of Ca
2? initiation points, the effect is not enough
to explain the reduction in number of Ca
2? initiation
points.
Is the effect of K201 on Ca
2? waves related
to b-adrenergic antagonism?
It is possible that the effect of K201 to reduce diastolic
Ca
2? release event amplitude and number of initiation
points in this study is due to an ability of K201 to antag-
onise the effect of b-adrenergic stimulation. While the
results in Fig. 5 cannot discount this hypothesis, it seems
unlikely given that in the sub-set of cells where Ca
2?
waves were produced in the absence of b-adrenergic
stimulation, the effect of K201 to limit these Ca
2? waves
was identical to that in the presence of b-adrenergic stim-
ulation (Fig. 4).
Summary and conclusion
The anti-arrhythmic effect of K201 has been attributed to
reducing the open probability of RyR2 thus preventing
excessive diastolic SR mediated Ca
2? leak [26]. This study
provides several new mechanistic insights which advance
our knowledge of K201. For the ﬁrst time, we have exam-
ined the effect of K201 on intracellular Ca
2? and contractile
function of isolated rat cardiomyocytes and have shown the
drug signiﬁcantly inhibits diastolic Ca
2? release and their
associated contractile events leading to an increased action
potential-induced SR Ca
2? release. These effects occur in
the absence of altered myoﬁlament Ca
2? sensitivity. Our
data also provide greater insight into the effect of K201 on
the spatiotemporal properties of Ca
2? handling introducing
the concept that a reduction in Ca
2? wave initiation points
has the potential to be anti-arrhythmic due to the limitation
of the amplitude of the Ca
2? wave and subsequent increase
in transient inward current. This may therefore be a route
through which both the deleterious arrhythmogenic and
mechanical effects of Ca
2? waves can be limited.
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